The Clinical Efficacy of Small Dose CAG Program in Comparison with MA Program in Senile Patients with Acute Myeloid Leukemia.

Li-Juan WANG; Xi-Feng WU; Ling SUN; Wei ZHUANG; Qiang SONG

Return

The Clinical Efficacy of Small Dose CAG Program in Comparison with MA Program in Senile Patients with Acute Myeloid Leukemia.

Author: Li-Juan WANG ¹ ; Xi-Feng WU ¹ ; Ling SUN ¹ ; Wei ZHUANG ² ; Qiang SONG ³
Author Information

1. Department of hematology,Laiwu People's Hospital, Laiwu 271100, Shandong Province, China.
2. Department of laboratory Examination,Laiwu People's Hospital, Laiwu 271100, Shandong Province, China.
3. Department of hematology, Qilu Hospital, Shandong University, Jinan 250012, Shandong Province, China.E-mail：ggtgyx1@126.com.
Publication Type:Journal Article
MeSH: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome
From: Journal of Experimental Hematology 2018;26(4):1050-1055
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo compare the clinical efficacy of small dose CAG regimen and MA regimen in the senile patients with acute myeloid leukemia(AML).
METHODSThe clinical data of 83 senile patients with AML from Sep. 2012 to Sep. 2016 in our Hospital were analyzed retrospectively. According to the chemotherapy regimens, the patients were divided into CAG group and MA group; 36 patients in CAG group were treated with small dose CAG, while 47 patients in MA group were treated with MA. The curative efficiency(CR rate, PR rate,NR rate and OR rate), side effect (myelosuppression,infection,intestinal discomfort and hemorrage), serum cytokines(IL-6，IL-17，TGFβ）, and prognosis(survival rate in 2 years, MST and SST) were observed, compared and studied in these 2 group.
RESULTSThe curative efficiency, CR rate and PR rate of the CAG group were not significantly different from that of the MA group (P>0.05）. The side effect in CAG group was significantly lower than that in the MA group (P<0.05）. The levels of serum cytokines of the MA group were lower than those of the CAG group. Additionally, the prognosis was not significantly different between 2 groups(P>0.05）.
CONCLUSIONFor senile patients with acute myeloid leukemia, compared with traditional MA regimen, the small dose CAG has a certain curative efficacy and survival rate, and the incidence of side effect reduced. Therefore, the small dose CAG is superior to MA for the senile patients with acute myeloid leukemia.